[Dose-dependent effects of cortexin in chronic cerebral ischemia (results of a multicenter randomized controlled study)].

Fedin AI, Belskaya GN, Kurushina OV, Kovalchuk VV, Starych EV, Chichanovskaya LV, Baranova OA

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2018Cited by 16 (Europe PMC)

PMID30335070DOI10.17116/jnevro201811809135PepBankPUB-30335070

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In chronic cerebral ischemia, Cortexin showed dose-dependent effects on neurological disorders, asthenia and sleep disturbance without separate outcome estimates.
In plain wordsIn chronic cerebral ischemia, Cortexin effects on neurological disorders, asthenia and sleep disturbance depended on dose.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
Direction not reportedDose-dependent neurological, asthenia and sleep response
Study
n = 189
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
10 mg or 20 mg · intramuscular · 10-day course repeated after 6 monthsAs given in this study (human).
Source sentences
Summary
A dose-dependent effect of cortexin on the severity of neurological disorders, asthenia, sleep disturbance was shown.
3 context sentences(design, population, supporting numbers)
Summary · context
The multicenter randomized controlled study included 189 patients with CCI, 42 (22.2%) men and 147 (77.8%) women, mean age 64.3±0.5 years.
Summary · context
Group 1 received intramuscular injection of 20 mg of cortexin, group 2 received 10 mg of cortexin; group 3 received basic treatment only.
Summary · context
The duration of treatment was 10 days, the treatment course was repeated after 6 months.
Report a problemFND-3033507001
02HumanRandomized controlled trialEfficacy outcome
In chronic cerebral ischemia, Cortexin's antidepressant effect after repeated courses was insignificant.
In plain wordsIn chronic cerebral ischemia, Cortexin's antidepressant effect after repeated courses was insignificant.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
No significant changeDepressive symptoms after repeated courses
Study
n = 189
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
Dose not stated · intramuscular · 10-day course repeated after 6 monthsAs given in this study (human).
Source sentences
Summary
Antidepressant and anxiolytic effects were insignificant and were determined after repeated courses of the drug.
3 context sentences(design, population, supporting numbers)
Summary · context
The multicenter randomized controlled study included 189 patients with CCI, 42 (22.2%) men and 147 (77.8%) women, mean age 64.3±0.5 years.
Summary · context
Group 1 received intramuscular injection of 20 mg of cortexin, group 2 received 10 mg of cortexin; group 3 received basic treatment only.
Summary · context
The duration of treatment was 10 days, the treatment course was repeated after 6 months.
Report a problemFND-3033507002
03HumanRandomized controlled trialEfficacy outcome
In chronic cerebral ischemia, Cortexin's anxiolytic effect after repeated courses was insignificant.
In plain wordsIn chronic cerebral ischemia, Cortexin's effect on anxiety after repeated courses was insignificant.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
No significant changeAnxiety after repeated courses
Study
n = 189
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
Dose not stated · intramuscular · 10-day course repeated after 6 monthsAs given in this study (human).
Source sentences
Summary
Antidepressant and anxiolytic effects were insignificant and were determined after repeated courses of the drug.
3 context sentences(design, population, supporting numbers)
Summary · context
The multicenter randomized controlled study included 189 patients with CCI, 42 (22.2%) men and 147 (77.8%) women, mean age 64.3±0.5 years.
Summary · context
Group 1 received intramuscular injection of 20 mg of cortexin, group 2 received 10 mg of cortexin; group 3 received basic treatment only.
Summary · context
The duration of treatment was 10 days, the treatment course was repeated after 6 months.
Report a problemFND-3033507003
04HumanRandomized controlled trialMechanism
In chronic cerebral ischemia, laboratory data confirmed an antioxidant effect of cortexin regardless of dose (10 mg or 20 mg), without a reported magnitude.
In plain wordsIn chronic cerebral ischemia, laboratory tests confirmed an antioxidant effect of cortexin at both 10 mg and 20 mg.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
Direction not reportedAntioxidant effect regardless of dose
Study
n = 189
Outcome group
Oxidative stress · Nervous system and cognition
Studied dose
10 mg or 20 mg · intramuscular · 10-day course repeated after 6 monthsAs given in this study (human).
Source sentences
Summary
The laboratory data confirmed the antioxidant effect regardless of the dose of cortexin.
3 context sentences(design, population, supporting numbers)
Summary · context
The multicenter randomized controlled study included 189 patients with CCI, 42 (22.2%) men and 147 (77.8%) women, mean age 64.3±0.5 years.
Summary · context
Group 1 received intramuscular injection of 20 mg of cortexin, group 2 received 10 mg of cortexin; group 3 received basic treatment only.
Summary · context
The duration of treatment was 10 days, the treatment course was repeated after 6 months.
Report a problemFND-3033507004
05HumanRandomized controlled trialMechanism
In patients with chronic cerebral ischemia, laboratory data confirmed an antioxidant effect of cortexin regardless of dose (10 mg or 20 mg), with no magnitude reported.
In plain wordsIn patients with chronic cerebral ischemia, lab tests confirmed an antioxidant effect of cortexin at both 10 mg and 20 mg.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
Direction not reportedAntioxidant effect (oxidative stress markers)
Study
n: not reported in source
Outcome group
Oxidative stress · Nervous system and cognition
Studied dose
10 mg or 20 mg · intramuscular · 10-day course repeated after 6 monthsAs given in this study (human).
Source sentences
Summary
The laboratory data confirmed the antioxidant effect regardless of the dose of cortexin.
3 context sentences(design, population, supporting numbers)
Summary · context
The multicenter randomized controlled study included 189 patients with CCI, 42 (22.2%) men and 147 (77.8%) women, mean age 64.3±0.5 years.
Summary · context
Group 1 received intramuscular injection of 20 mg of cortexin, group 2 received 10 mg of cortexin; group 3 received basic treatment only.
Summary · context
The duration of treatment was 10 days, the treatment course was repeated after 6 months.
Report a problemFND-3033507005
06HumanRandomized controlled trialSafety outcome
In patients with chronic cerebral ischemia, the study reported safety and good tolerability of cortexin without event counts.
In plain wordsIn patients with chronic cerebral ischemia, the study reported that cortexin was safe and well tolerated, with no event counts given.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
Direction not reportedSafety and tolerability
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
10 mg or 20 mg · intramuscular · 10-day course repeated after 6 monthsAs given in this study (human).
Source sentences
Summary
The safety and good tolerability of the drug were shown.
3 context sentences(design, population, supporting numbers)
Summary · context
The multicenter randomized controlled study included 189 patients with CCI, 42 (22.2%) men and 147 (77.8%) women, mean age 64.3±0.5 years.
Summary · context
Group 1 received intramuscular injection of 20 mg of cortexin, group 2 received 10 mg of cortexin; group 3 received basic treatment only.
Summary · context
The duration of treatment was 10 days, the treatment course was repeated after 6 months.
Report a problemFND-3033507006

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.